Product Description
Methylergometrine is a semisynthetic ergot alkaloid and a derivative of ergonovine and is used for the prevention and control of postpartum and post-abortion hemorrhage. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Methylergonovine#section=Pharmacology-and-Biochemistry)
Mechanisms of Action: Apoptosis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular,Intravenous,Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Algeria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | Czech | Denmark | Dominican Republic | Ecuador | Egypt | France | Greece | Iceland | India | Indonesia | Ireland | Italy | Jordan | Korea | Luxembourg | Malaysia | Malta | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Saudi Arabia | Serbia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|